Rare earth medical applications span diagnostics, oncology, and surgical hardware — with gadolinium-based contrast agents used in approximately one in three MRI scans globally, and lutetium-177 radiopharmaceuticals now forming the backbone of targeted neuroendocrine tumour therapy following FDA approval. The 17 rare earth elements contribute unique magnetic, luminescent, and radioactive properties that no common substitute currently replicates at clinical scale.
This guide covers the ten most commercially significant rare earth medical applications, ranked by clinical adoption and supply chain relevance for the REE sector.
How We Ranked These Rare Earth Medical Applications
Rankings reflect three criteria: scale of clinical deployment, regulatory approval status, and dependence on a specific rare earth element with no near-term substitute. Applications where a rare earth is incidental or easily replaced are excluded.
1. Gadolinium MRI Contrast Agents
Primary element: Gadolinium (Gd)
Gadolinium-based contrast agents (GBCAs) are injected intravenously to enhance image clarity during magnetic resonance imaging. The gadolinium ion’s seven unpaired electrons alter the relaxation times of surrounding water protons, sharpening visualisation of tumours, vascular lesions, and inflammation. GBCAs account for an estimated 82% of all MRI contrast agent use and are administered in roughly 38–42% of the 135 million MRI procedures performed annually worldwide.
The global MRI contrast agents market was valued at approximately $1.69 billion in 2026, forecast to reach $2.42 billion by 2031 at a 7.5% CAGR, according to Mordor Intelligence. Macrocyclic formulations — which have lower gadolinium tissue retention — now account for close to 64% of GBCA use as regulators push toward safer formulations. Gadolinium is mined primarily as a co-product of light rare earth processing and is not produced in isolation at commercial scale.
2. Lutetium-177 Cancer Radiotherapy
Primary element: Lutetium (Lu)
Lutetium-177 (¹⁷⁷Lu) is the active radionuclide in peptide receptor radionuclide therapy (PRRT), the most precise form of systemic radiotherapy currently in clinical use. The FDA approved lutetium Lu 177 dotatate (Lutathera) in January 2018 for somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs). In the pivotal NETTER-1 trial, ¹⁷⁷Lu-dotatate reduced the hazard of progression or death by 79% compared with high-dose octreotide.
A radioequivalent formulation (PNT2003, developed by Lantheus) received FDA tentative approval in early 2026, with full commercial availability anticipated after expiry of the 30-month regulatory exclusivity stay in June 2026. The 12-month progression-free survival rate in the supporting OZM-067 trial was 81%. Lutetium-177 supply is sourced from nuclear reactors that irradiate natural ytterbium or enriched lutetium targets — a production process entirely separate from conventional REE mining but dependent on the same rare earth feedstock. Demand is growing faster than reactor capacity in several Western markets.
3. Holmium Laser Surgery
Primary element: Holmium (Ho)
Holmium:YAG (Ho:YAG) solid-state lasers operate at 2,100 nanometres, a wavelength that is strongly absorbed by water and soft tissue. This makes holmium the preferred laser medium for endoscopic urological procedures: the Ho:YAG platform can pulverise kidney stones of any composition (a technique called laser lithotripsy), resect the prostate (HoLEP), and ablate bladder tumours — all without open surgery. Holmium lasers are also used in orthopaedic arthroscopy and soft tissue incision.
The holmium laser lithotripsy market has grown rapidly alongside single-use flexible ureteroscope adoption, with pulse-modulated “Moses” and thulium fibre laser technologies extending the clinical envelope. Holmium is a heavy rare earth element produced predominantly as a by-product of ionic clay deposits in southern China. Western supply remains limited to co-production streams at facilities such as Energy Fuels’ White Mesa Mill.
4. Neodymium Magnets in Medical Hardware
Primary element: Neodymium (Nd), with dysprosium (Dy) additions for thermal stability
Neodymium-iron-boron (NdFeB) permanent magnets produce the highest energy density of any commercially available magnet. In medical hardware, they are embedded in pacemakers and implantable cardiac devices, integrated into hearing aids and bone-anchored hearing systems, used in MRI-compatible surgical tools, and deployed in open-configuration MRI machines that require compact field-generating assemblies. The drive toward miniaturisation in implantable devices has made NdFeB the default choice where bulk and power consumption are constrained.
Dysprosium additions of 2–6% by weight are used in NdFeB grades intended for applications above 150°C — relevant for sterilisation cycles and some imaging environments. For full supply chain context on this element, see our top 10 neodymium uses guide and the what is neodymium explainer.
5. Yttrium-90 Selective Internal Radiation Therapy
Primary element: Yttrium (Y)
Yttrium-90 (⁹⁰Y) microspheres are used in selective internal radiation therapy (SIRT), a procedure in which radioactive glass or resin beads are injected via catheter into the hepatic artery to deliver localised beta radiation directly to liver tumours. The technique treats primary hepatocellular carcinoma and metastatic colorectal cancer in the liver without systemic chemotherapy exposure. Two FDA-approved products — TheraSphere (glass microspheres, BTG/Boston Scientific) and SIR-Spheres (resin microspheres, Sirtex) — dominate the market.
⁹⁰Y is produced by neutron irradiation of yttrium-89 in nuclear reactors. Natural yttrium, mined as a co-product of rare earth operations, is the sole feedstock. Yttrium’s role across medical, phosphor, and superconductor applications makes it one of the more commercially significant heavy rare earths outside the magnet suite.
6. Terbium and Europium X-ray Phosphors
Primary elements: Terbium (Tb), Europium (Eu)
Terbium-doped gadolinium oxysulphide (Gd₂O₂S:Tb) is the standard green-emitting scintillator phosphor in digital X-ray detectors and computed radiography screens. It converts ionising X-ray photons into visible light with high efficiency, allowing detector sensitivity to be maintained at reduced patient dose. Europium-activated phosphors are used in the red-emission channel of earlier flat-panel systems and remain active in certain radiographic applications.
The transition from film-screen systems to flat-panel digital detectors — now essentially complete in OECD markets — has locked terbium and europium into the global radiography installed base of several hundred thousand units. For a detailed breakdown of terbium end-uses, see top 10 terbium uses and the what is terbium explainer.
7. Lanthanum Carbonate for Renal Disease
Primary element: Lanthanum (La)
Lanthanum carbonate (Fosrenol, Shire/Takeda) is an FDA-approved oral phosphate binder prescribed to patients with end-stage renal disease on dialysis. Patients with chronic kidney failure cannot excrete dietary phosphorus normally; phosphate accumulation drives secondary hyperparathyroidism, vascular calcification, and elevated cardiovascular mortality. Lanthanum ions bind phosphate in the gastrointestinal tract with high affinity across a wide pH range, preventing absorption before excretion occurs.
Lanthanum carbonate does not require dose adjustment for hepatic impairment and is minimally absorbed systemically — a key safety advantage over aluminium-based alternatives. The chronic kidney disease phosphate binder market is substantial: the global dialysis population exceeds 3.5 million patients, with lanthanum carbonate competing against calcium-based binders and sevelamer. This application makes lanthanum one of the few rare earths with a direct pharmaceutical end-use consuming the refined element.
8. Samarium-153 Bone Pain Palliation
Primary element: Samarium (Sm)
Samarium-153 lexidronam (Quadramet, Lantheus) is an intravenous radiopharmaceutical licensed for pain palliation in patients with bone metastases from cancers including prostate, breast, and lung. The ¹⁵³Sm isotope is chelated to EDTMP, a phosphonate compound that targets areas of elevated bone turnover. Beta radiation is delivered locally to metastatic lesions, reducing pain and compressive nerve effects within one to two weeks of administration. The effective range of ¹⁵³Sm beta particles in tissue is approximately 3 mm, limiting dose to adjacent normal bone marrow.
¹⁵³Sm is produced by neutron irradiation of enriched samarium-152 targets. Natural samarium, refined from bastnäsite or monazite concentrates, is the feedstock. Although samarium-cobalt (SmCo) permanent magnets represent the larger commercial samarium application, the radiopharmaceutical use is clinically significant and supply-chain distinct.
9. Rare Earth Alloys in Bioresorbable Implants
Primary elements: Yttrium (Y), Gadolinium (Gd), Cerium (Ce)
Magnesium-based bioresorbable implants — bone plates, screws, and cardiovascular stents designed to dissolve safely in the body after healing — require alloying additions to control mechanical strength and corrosion rate. Rare earth elements added at 1–4% by weight (typically yttrium, gadolinium, or cerium) dramatically improve the fracture toughness and degradation kinetics of the magnesium matrix, preventing premature failure before tissue regeneration is complete.
Commercial products are available in orthopaedics (Synbone, Depuy Synthes development programmes) and vascular surgery. The bioresorbable implant segment is small in current volume terms but represents one of the few applications where rare earth content is locked into a single-patient, single-use device with no recovery pathway — a structural driver of incremental demand as adoption expands.
10. Europium Fluorescent Probes in Diagnostics
Primary element: Europium (Eu)
Europium chelate nanoparticles are used as fluorescent labels in time-resolved fluorescence immunoassays (TR-FIA) and lateral flow diagnostic kits. The long fluorescence lifetime of europium complexes (microseconds, versus nanoseconds for organic fluorophores) allows background autofluorescence from biological samples to be eliminated by time-gating — substantially improving signal-to-noise ratio and detection sensitivity. This enables quantification of proteins, hormones, cardiac biomarkers, and pathogen antigens at concentrations below those detectable with conventional colorimetric tests.
Europium-based diagnostics are embedded in hospital point-of-care testing systems including troponin assays for myocardial infarction diagnosis. The what is europium page covers the element’s broader supply chain and luminescent properties in detail. Demand for in vitro diagnostic kits accelerated significantly after 2020 and has not returned to pre-pandemic levels in the professional testing segment.
Rare Earth Medical Applications — Summary Table
| Application | Element | Clinical Use | Regulatory Status |
|---|---|---|---|
| MRI contrast agents | Gadolinium (Gd) | Diagnostic imaging | FDA/EMA approved |
| PRRT cancer therapy | Lutetium (Lu) | Neuroendocrine tumours | FDA approved (2018) |
| Ho:YAG laser surgery | Holmium (Ho) | Urology, orthopaedics | FDA cleared |
| NdFeB medical magnets | Neodymium (Nd) | Pacemakers, hearing aids, MRI | Device-level approval |
| SIRT liver therapy | Yttrium (Y) | Liver cancer treatment | FDA approved |
| X-ray phosphors | Terbium (Tb), Europium (Eu) | Digital radiography | Established standard |
| Phosphate binder | Lanthanum (La) | Renal disease management | FDA approved |
| Bone pain palliation | Samarium (Sm) | Metastatic cancer pain | FDA approved |
| Bioresorbable implants | Yttrium, Gadolinium, Cerium | Orthopaedics, vascular | CE marked / development |
| Fluorescent diagnostics | Europium (Eu) | Point-of-care testing | Established standard |
The Outlook for Rare Earth Medical Applications
The radiopharmaceutical sector is the fastest-moving segment: lutetium-177 demand is expanding ahead of reactor production capacity, and actinium-225 — which requires radium-226 feedstocks with their own supply constraints — is entering late-stage trials for prostate cancer. Gadolinium contrast demand remains structurally resilient despite safety scrutiny, with macrocyclic formulations and lower-dose protocols extending the market. Supply chain risk for medical rare earths is concentrated in lutetium and holmium, both heavy rare earths produced primarily as minor co-products of Chinese ionic clay mining. Any supply disruption affecting Chinese HREE output would affect medical isotope production timelines with a 12–18 month lag, the time required to activate alternative feedstock and reactor capacity.
This article is for informational purposes only and does not constitute investment advice. Market data is subject to revision.
What rare earth elements are used in medicine?
The main rare earth elements used in medicine are gadolinium (MRI contrast agents), lutetium (cancer radiotherapy), holmium (surgical lasers), neodymium (permanent magnets in pacemakers and hearing aids), yttrium (liver cancer treatment and X-ray phosphors), terbium (digital radiography screens), lanthanum (kidney disease treatment), samarium (bone pain therapy), and europium (diagnostic test kits).
What is lutetium-177 used for in cancer treatment?
Lutetium-177 (¹⁷⁷Lu) is the active radionuclide in peptide receptor radionuclide therapy (PRRT), an FDA-approved treatment for somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs). The drug, sold as Lutathera, reduced the risk of disease progression by 79% in the pivotal NETTER-1 trial compared with standard therapy. A generic radioequivalent received FDA tentative approval in 2026.
Why is gadolinium used in MRI scans?
Gadolinium’s seven unpaired electrons make it strongly paramagnetic, causing it to alter the relaxation times of nearby water protons when injected as a contrast agent. This dramatically improves soft tissue differentiation in MRI images, helping radiologists identify tumours, vascular abnormalities, and areas of inflammation. Gadolinium-based contrast agents are used in approximately one in three MRI scans globally.
What is holmium used for in surgery?
Holmium is the lasing medium in Ho:YAG solid-state lasers, which operate at 2,100 nanometres. This wavelength is strongly absorbed by water and soft tissue, making holmium lasers the standard tool for kidney stone fragmentation (laser lithotripsy), prostate resection (HoLEP), bladder tumour ablation, and orthopaedic arthroscopy — all performed endoscopically without open surgery.
Are rare earth medical applications at risk from supply disruptions?
Lutetium and holmium — both heavy rare earths — carry the highest supply risk. Both are produced predominantly as minor co-products of ionic clay mining in southern China. A disruption to Chinese HREE exports would affect medical isotope feedstock availability with an estimated 12–18 month lag, the time needed to activate alternative reactor feedstock supply chains. Gadolinium and neodymium carry lower near-term supply risk due to broader production geography.
